DelveInsight’s, “Cytokine Release Syndrome – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Cytokine Release Syndrome Understanding
Cytokine Release Syndrome: Overview
A condition that may occur after treatment with some types of immunotherapy, such as monoclonal antibodies and CAR-T cells. Cytokine release syndrome is caused by a large, rapid release of cytokines into the blood from immune cells affected by the immunotherapy. Cytokines are immune substances that have many different actions in the body.
Signs and symptoms of cytokine release syndrome include fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing. Most patients have a mild reaction, but sometimes, the reaction may be severe or life threatening.
As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important. Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome.
Cytokine Release Syndrome Emerging Drugs Chapters
This segment of the Cytokine Release Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytokine Release Syndrome Emerging Drugs
• Canakinumab: Novartis
Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.
• Itacitinib: Incyte Corporation
Itacitinib is a potent, selective JAK1 inhibitor which is being clinically evaluated in several inflammatory diseases. It is currently being evaluated in phase II stage for the prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy.
• Dapansutrile: Olatec Therapeutics LLC
Dapansutrile is being developed by Olatec Therapeutics LLC for the treatment of Cytokine Release Syndrome. It is currently being evaluated in phase II trial to determine safety and efficacy of Dapansutrile for treatment of moderate COVID-19 symptoms and evidence of Early Cytokine Release Syndrome.
Further product details are provided in the report……..
Cytokine Release Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Cytokine Release Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Cytokine Release Syndrome
There are approx. 5+ key companies which are developing the therapies for Cytokine Release Syndrome. The companies which have their Cytokine Release Syndrome drug candidates in the most advanced stage, i.e. phase III include Novartis and others
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Cytokine Release Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Monoclonal antibodies
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cytokine Release Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytokine Release Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytokine Release Syndrome drugs.
• The companies and academics are working to assess challenges and seek opportunities that could influence Cytokine Release Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Cytokine Release Syndrome.
• In July 2020, India's medical authorities approve Biocon Biologic's itolizumab, an anti-CD6 IgG1 monoclonal antibody, for emergency treatment of cytokine release syndrome in patients with coronavirus disease 2019 (COVID-19).
Cytokine Release Syndrome Report Insights
• Cytokine Release Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Cytokine Release Syndrome Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cytokine Release Syndrome drugs?
• How many Cytokine Release Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytokine Release Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cytokine Release Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cytokine Release Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?
• Biocon Limited
• Olatec Therapeutics LLC
• Novartis Pharmaceuticals